
|Articles|February 23, 2011
National Comprehensive Cancer Network Guideline Updates From the 15th Annual Congress
Advertisement
Credits: 1.0 contact hours (0.10 CEUs)
Anthony Elias, MD, Professor of Medicine, Medical Director, Breast Cancer and Sarcoma Programs, University of Colorado Cancer Center
Educational Objectives
After completing this activity, participants should be able to:
- List some of the major National Comprehensive Cancer Network (NCCN) practice guideline revisions presented at the 15th Annual Congress
- Identify select NCCN guideline revisions that may impact the course of treatment in a given case
- Discuss the use of patient characteristics to determine therapeutic management in select NCCN guideline revisions
Target Audience: Pharmacy directors/administrators, clinical pharmacists practicing in managed care environments, and any other pharmacist practitioners involved in the care of patients diagnosed with cancer.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
3
ACA Subsidy Expiration Raises Concerns for Behavioral Health Access and ED Strain
4
HIV in 2025 Defined by Challenges Throughout the Year, Despite Some Advances
5









































